Chemoprevention in Lynch syndrome

Familial Cancer

Volumn 12, Issue 4, 2013, Pages 707-718

  Burn, John ^a   Mathers, John C ^a   Bishop, D Tim ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Aspirin; Chemoprevention; Genetic predisposition; Mismatch repair gene defects; Resistant starch

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; PROTON PUMP INHIBITOR; STARCH;

ADENOMA; APOPTOSIS; ARTICLE; ASCENDING COLON; CANCER INCIDENCE; CANCER PATIENT; CANCER PREVENTION; CANCER PROGNOSIS; CHEMOPROPHYLAXIS; COLON POLYP; COLONOSCOPY; CONTROLLED CLINICAL TRIAL (TOPIC); CRYPT CELL; DESCENDING COLON; DIGESTIVE SYSTEM ULCER; DRUG DOSE COMPARISON; ENDOMETRIUM CANCER; ENTERIC COATED TABLET; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; LOW RISK POPULATION; MEDICATION COMPLIANCE; MISMATCH REPAIR; MUTATION; PRIORITY JOURNAL; RISK REDUCTION; TABLET; TRANSVERSE COLON;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL AGENCIES; INTERVENTION STUDIES; MALE; PROGNOSIS; STARCH;

EID: 84888157758     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-013-9650-y     Document Type: Article

References (33)

1. Fishel R, Lescoe MK, Rao MRS, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R (1993) The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75:1027-1038
2. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JW, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJ, Vasen HF, Barker G, Crawford G, Elliott F, Movahedi M, Pylvanainen K, Wijnen JT, Fodde R, Lynch HT, Mathers JC, Bishop DT, CAPP2 Investigators (2011) Lancet 378(9809):2081-2087
3. Kune GA, Kune S, Watson LF (1988) Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48:4399-4404
4. Thun MJ, Namboodiri MM, Heath CW Jr (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593-1596
5. Cassidy A, Bingham SA, Cummings JH (1994) Starch intake and colorectal cancer risk: an international comparison. Br J Cancer (Lond) 69:937-942
6. Aune D, Chan DS, Lau R, Vieira R, Greenwood DC, Kampman E, Norat T (2011) Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. BMJ 343:d6617
7. Hylla S, Gostner A, Dusel G, Anger H, Bartram H-P, Christl SU, Kasper H, Scheppach W (1998) Effects of resistant starch on the colon in healthy volunteers: possible implications for cancer prevention. Am J Clin Nutr 67:136-142
8. Grubben MJ, Braak CVD, Essenberg M, Olthof M, Tangerman A, Katan M, Nagengast F (2001) Effect of resistant starch on potential biomarkers for colonic cancer risk in patients with colonic adenomas: a controlled trial. Dig Dis Sci 46:750-756
9. Williams EA, Coxhead JM, Mathers JC (2003) Anti-cancer effects of butyrate: use of micro-array technology to investigate mechanisms. Proc Nutr Soc 62:107-115
10. van Munster IP, Tangerman A, Nagengast FM (1994) Effect of resistant starch on colonic fermentation, bile acid metabolism, and mucosal proliferation. Dig Dis Sci 39:834-842
11. Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, Dunlop MG, Eccles D, Ellis A, Evans DG, Fodde R, Maher ER, Moslein G, Vasen HF, Coaker J, Phillips RK, Bulow S, Mathers JC (2011) A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) 4:655-665
12. Burn J, Bishop DT, Mecklin J-P, Macrae F, Moslein G, Olschwang S, Bisgaard M-L, Ramesar R, Eccles D, Maher ER, Bertario L, Jarvinen HJ, Lindblom A, Evans DG, Lubinski J, Morrison PJ, Ho JWC, Vasen HFA, Side L, Thomas HJW, Scott RJ, Dunlop M, Barker G, Elliott F, Jass JR, Fodde R, Lynch HT, Mathers JC, CAPP2 Investigators (2008) Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 359:2567-2578
13. Liljegren A, Barker G, Elliott F, Bertario L, Bisgaard ML, Eccles D, Evans G, Macrae F, Maher E, Lindblom A, Rotstein S, Nilsson B, Mecklin JP, Moslein G, Jass J, Fodde R, Mathers J, Burn J, Bishop DT (2008) Prevalence of adenomas and hyperplastic polyps in mismatch repair mutation carriers among CAPP2 participants: report by the colorectal adenoma/carcinoma prevention programme 2. J Clin Oncol 26:3434-3439
14. Vasen HF, Moslein G, Alonso A, Bernstein I, Bertario L, Blanco I, Burn J, Capella G, Engel C, Frayling I, Friedl W, Hes FJ, Hodgson S, Mecklin JP, Moller P, Nagengast F, Parc Y, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Wijnen J (2007) Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44:353-362
15. Mathers JC, Movahedi M, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans G, Maher ER, Bertario L, Bisgaard ML, Dunlop M, Ho JW, Hodgson S, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJ, Vasen H, Gerdes AM, Barker G, Crawford G, Elliott F, Pylvanainen K, Wijnen J, Fodde R, Lynch H, Bishop DT, Burn J, Investigators C (2012) Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet Oncol 13:1242-1249
16. Dronamraju SS, Coxhead JM, Kelly SB, Mathers JC (2010) Differential antineoplastic effects of butyrate in cells with and without a functioning DNA mismatch repair. Nutr Cancer 62:105-115
17. Din FV, Theodoratou E, Farrington SM, Tenesa A, Barnetson RA, Cetnarskyj R, Stark L, Porteous ME, Campbell H, Dunlop MG (2010) Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 59:1670-1679
18. Borthwick GM, Johnson AS, Partington M, Burn J, Wilson R, Arthur HM (2006) Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. FASEB J 20:2009-2016
19. Burn J, Chapman PD, Bishop DT, Mathers J (1998) Diet and cancer prevention: the concerted action polyp prevention (CAPP) studies. Proc Nutr Soc 57:183-186
20. Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, Tariverdian M, Benner A, von Knebel Doeberitz M (2008) Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 134:988-997
21. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun M (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10:501-507
22. Flossmann E, Rothwell PM (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369:1603-1613
23. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, Meade TW (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376:1741-1750
24. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE (1995) Aspirin and the risk of colorectal cancer in women. N Engl J Med 333:609-614
25. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377:31-41
26. Lynch HT, Smyrk T, Jass JR (1995) Hereditary nonpolyposis colorectal cancer and colonic adenomas: aggressive adenomas? Semin Surg Oncol 11:406-410
27. Vasen HFA, Moslein G, Alonso A et al (2007) Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44:353-362
28. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, Chaussade S, Baron JA (2009) Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 101:256-266
29. Jass JR, Walsh MD, Barker M, Simms LA, Young J, Leggett BA (2002) Distinction between familial and sporadic forms of colorectal cancer showing DNA microsatellite instability. Eur J Cancer 38:858-866
30. Chan AT, Ogino S, Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356:2131-2142
31. Ruschoff J, Wallinger S, Dietmaier W, Bocker T, Brockhoff G, Hofstadter F, Fishel R (1998) Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci USA 95:11301-11306
32. McIlhatton MA, Tyler J, Burkholder S, Ruschoff J, Rigas B, Kopelovich L, Fishel R (2007) Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. Cancer Res 67:10966-10975
33. McIlhatton MA, Tyler J, Kerepesi LA, Bocker-Edmonston T, Kucherlapati MH, Edelmann W, Kucherlapati R, Kopelovich L, Fishel R (2011) Aspirin and low-dose nitric oxide-donating aspirin increase life span in a Lynch syndrome mouse model. Cancer Prev Res (Phila) 4:684-693